These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 15915389)

  • 41. uPA and PAI-1 in rectal cancer--relationship to radiotherapy and clinical outcome.
    Angenete E; Langenskiöld M; Palmgren I; Falk P; Oresland T; Ivarsson ML
    J Surg Res; 2009 May; 153(1):46-53. PubMed ID: 18533186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
    Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression.
    Chen SC; Henry DO; Hicks DG; Reczek PR; Wong MK
    J Urol; 2009 Jan; 181(1):336-42. PubMed ID: 19010488
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
    Lamy PJ; Verjat T; Servanton AC; Paye M; Leissner P; Mougin B
    Am J Clin Pathol; 2007 Sep; 128(3):404-13. PubMed ID: 17709314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance.
    Alessi MC; Poggi M; Juhan-Vague I
    Curr Opin Lipidol; 2007 Jun; 18(3):240-5. PubMed ID: 17495595
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High concentrations of plasminogen activator inhibitor-1 in lungs of preterm infants with respiratory distress syndrome.
    Cederqvist K; Sirén V; Petäjä J; Vaheri A; Haglund C; Andersson S
    Pediatrics; 2006 Apr; 117(4):1226-34. PubMed ID: 16585319
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
    Takahashi T; Suzuki K; Ihara H; Mogami H; Kazui T; Urano T
    Semin Thromb Hemost; 2005 Jun; 31(3):356-63. PubMed ID: 16052409
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evolving role of uPA/uPAR system in human cancers.
    Dass K; Ahmad A; Azmi AS; Sarkar SH; Sarkar FH
    Cancer Treat Rev; 2008 Apr; 34(2):122-36. PubMed ID: 18162327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Involvement of plasminogen activator and plasminogen activator inhibitor type 1 in spermatogenesis, sperm capacitation, and fertilization.
    Liu YX
    Semin Thromb Hemost; 2007 Feb; 33(1):29-40. PubMed ID: 17253187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Regulation of PAI-1 expression].
    Wyrzykowska P; Kasza A
    Postepy Biochem; 2009; 55(1):46-53. PubMed ID: 19514465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Proceeding of revision for neoplasm staging by FIGO].
    Sagae S
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):203-6. PubMed ID: 21452498
    [No Abstract]   [Full Text] [Related]  

  • 54. The role of interleukin-6 in gynaecological malignancies.
    Coward JI; Kulbe H
    Cytokine Growth Factor Rev; 2012 Dec; 23(6):333-42. PubMed ID: 23031497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor interstitial fluid: misconsidered component of the internal milieu of a solid tumor.
    Freitas I; Baronzio GF; Bono B; Griffini P; Bertone V; Sonzini N; Magrassi GR; Bonandrini L; Gerzeli G
    Anticancer Res; 1997; 17(1A):165-72. PubMed ID: 9066647
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Thrombocytosis and solid tumors].
    Malacarne P; Gilli G; Lanza M; Indelli M
    Recenti Prog Med; 1988 Sep; 79(9):351-5. PubMed ID: 3201029
    [No Abstract]   [Full Text] [Related]  

  • 57. PAI-1 and vasculopathy: the debate continues.
    Schäfer K; Konstantinides S
    J Thromb Haemost; 2004 Jan; 2(1):13-5. PubMed ID: 14717960
    [No Abstract]   [Full Text] [Related]  

  • 58. [Gynecologic tumors].
    Hermanek P; Hutter RV; Sobin LH; Wagner G; Wittekind C
    Minerva Ginecol; 2000 Oct; 52(10):391-441. PubMed ID: 11236341
    [No Abstract]   [Full Text] [Related]  

  • 59. Is there a place for molecular biology markers and other prognostic factors in staging gynaecological tumours?
    Bösze P
    Eur J Gynaecol Oncol; 2000; 21(6):542-5. PubMed ID: 11214606
    [No Abstract]   [Full Text] [Related]  

  • 60. Preclinical invasive carcinoma. European Association of Gynecologists and Obstetricians: 1st meeting, London, 12-13 June 1986.
    Eur J Obstet Gynecol Reprod Biol; 1987 Apr; 24(4):255-69. PubMed ID: 3582714
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.